571 related articles for article (PubMed ID: 37539051)
1. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.
Shin E; Bak SH; Park T; Kim JW; Yoon SR; Jung H; Noh JY
Front Immunol; 2023; 14():1192907. PubMed ID: 37539051
[TBL] [Abstract][Full Text] [Related]
2. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M
J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457
[TBL] [Abstract][Full Text] [Related]
5. Engineering the next generation of CAR-NK immunotherapies.
Biederstädt A; Rezvani K
Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
[TBL] [Abstract][Full Text] [Related]
6. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
7. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
8. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
Lin C; Horwitz ME; Rein LAM
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
[TBL] [Abstract][Full Text] [Related]
9. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
10. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
Ruppel KE; Fricke S; Köhl U; Schmiedel D
Front Immunol; 2022; 13():822298. PubMed ID: 35371071
[TBL] [Abstract][Full Text] [Related]
11. Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer.
Daher M; Rezvani K
Cancer Discov; 2021 Jan; 11(1):45-58. PubMed ID: 33277313
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
Zhang C; Hu Y; Xiao W; Tian Z
Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.
Dash CP; Sonowal D; Dhaka P; Yadav R; Chettri D; Satapathy BP; Sheoran P; Uttam V; Jain M; Jain A
Front Immunol; 2024; 15():1390498. PubMed ID: 38694508
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside.
Zhang B; Yang M; Zhang W; Liu N; Wang D; Jing L; Xu N; Yang N; Ren T
Cell Death Dis; 2024 Jan; 15(1):50. PubMed ID: 38221520
[TBL] [Abstract][Full Text] [Related]
15. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review.
Hosseini M; Habibi Z; Hosseini N; Abdoli S; Rezaei N
Expert Opin Biol Ther; 2022 Mar; 22(3):349-366. PubMed ID: 34541989
[TBL] [Abstract][Full Text] [Related]
17. Next Generation Natural Killer Cells for Cancer Immunotherapy.
Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
Front Immunol; 2022; 13():886429. PubMed ID: 35720306
[TBL] [Abstract][Full Text] [Related]
18. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
19. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells.
Moscarelli J; Zahavi D; Maynard R; Weiner LM
Transplant Cell Ther; 2022 Oct; 28(10):650-656. PubMed ID: 35788086
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells: a promising immunotherapy for cancer.
Chu J; Gao F; Yan M; Zhao S; Yan Z; Shi B; Liu Y
J Transl Med; 2022 May; 20(1):240. PubMed ID: 35606854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
